|
Jubilant Pharmova Ltd announced credit rating actions from multiple agencies, including an unspecified agency assigning a credit rating to a not specified instrument with details not provided, and India Ratings and Research Pvt Ltd affirming the Rs 500 crore Bank Loan at IND AA with a Stable outlook, affirming the Long-Term Debt at IND A+ with a Stable outlook, and assigning a rating of IND AA+/Stable to proposed Non-Convertible Debentures of Rs 1,400.00; CRISIL upgraded the Commercial Paper from Rs 250 Crore from CRISIL A1 to CRISIL A1+; India Ratings assigned a rating of IND AA+/Stable to proposed Non-Convertible Debentures of 14,000, affirmed a Long Term Bank Loan of 500 crore at IND AAA with a Stable Outlook, and disseminated a rating communication received October 21, 2026, alongside a rating letter dated October 21, 2026, and a credible rating based on limited information; India Ratings & Research (A Fitch Group Company) issued a NCD rating letter dated October 21, 2026, while India Ratings and Research (Ind-Ra) assigned a rating of IND AA+/Stable to proposed non-convertible debentures (NCDs) of 14,000, all based on information from offering documents and reports, with additional rating data pending full text availability and no rating data found for Fitch Group or certain India Ratings & Research entities.
|